Clinical Trials

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

32 enrolled

Endometrial Neoplasms

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05036434 2026-01-23

ACCOMPLISH

Endocrine

Adrenocortical Carcinoma

NCT04207086 2025-12-16

Neo PeLe

21 enrolled

Melanoma

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05282901 2025-11-24

PLUME

51 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT04869137 2025-10-31

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

26 enrolled

Skin Neoplasms, Carcinoma, Merkel Cell

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

64 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

3 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT05822752 2025-08-14

LIVIGNO-1

130 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

High Grade Fallopian Tube Serous Adenocarcinoma

NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

35 enrolled

Thoracic

NSCLC

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

6 enrolled 11 charts

Uveal Melanoma, Melanoma

NCT02780310 2025-06-05

Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

33 enrolled

Carcinoma, Adenoid Cystic

NCT04976634 2025-04-06

MK-6482-016

730 enrolled

Tumor-Agnostic

Neoplasms

NCT04393350 2025-02-26

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

18 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04745988 2024-11-15

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT04287829 2024-11-05

PEMMELA

Other solid neoplasmThoracic

58 enrolled

Mesothelioma, Malignant

NCT05258279 2024-08-28

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Thoracic

Non-squamous Non-small-cell Lung Cancer

NCT06138769 2024-07-03

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

50 enrolled